紫龙金片对肺癌患者术后免疫功能的调节作用
|
摘要
目的从体液免疫及细胞免疫角度探讨紫龙金片对肺癌患者术后免疫功能的调节作用。方法将60例肺癌术后患者按数字随机表分为2组,对照组及治疗组各30例。对照组术后给予常规支持治疗,治疗组在术后常规支持治疗基础上第3天起口服紫龙金片(每次4片,3次/d)治疗,比较两组患者的免疫球蛋白(IgA、IgG、IgM)、T细胞亚群(CD3~+、CD4~+、CD8~+、CD4~+/CD8~+)及NK细胞等指标。结果术后第2天两组IgA、IgG、IgM、CD3~+、CD4~+、CD4~+/CD8~+与术前比较均下降,差异显著(P<0.05),CD8~+差异不显著(P>0.05);术后第14天对照组及治疗组IgA、IgG、IgM、CD3~+、CD4~+、CD4~+/CD8~+、NK与术后第2天比较均有上升,对照组NK差异显著(P<0.05),治疗组IgA、IgG、IgM、CD3~+、CD4~+、CD4~+/CD8~+差异显著(P<0.05);术后第14天治疗组Ig A、Ig G、CD4~+、CD4~+/CD8~+、NK与对照组比较,均显著升高(P<0.05)。结论肺癌患者手术后早期存在免疫功能抑制状态,紫龙金片可以改善肺癌患者术后体液免疫和细胞免疫功能,促进机体免疫功能恢复,增强机体抗肿瘤能力。
Objective To explore the regulatory effect of Zilongjin Tablet on immune function of postoperative patients with lung cancer from humoral immunity and cellular immunity, and to seek an effective method for comprehensive treatment of lung cancer.Methods Sixty patients with lung cancer after operation were divided into two groups according to the digital random table, 30 in the control group and 30 in the treatment group. The control group was given routine supportive treatment after operation. The treatment group was given Zilongjin Tablets(4 tablets, 3 times/d) with routine supportive treatment on day 3 after operation. The indexes of immunoglobulin(IgA, IgG, IgM), T lymphocyte subsets(CD3~+, CD4~+, CD8~+, CD4~+/CD8~+), and NK cells were compared between the two groups. Results On day 2 after operation, IgA, IgG, IgM, CD3~+, CD4~+, CD4~+/CD8~+ in the two groups decreased compared with those before operation, and the difference was statistically significant(P < 0.05), but there was no significant difference in CD8~+(P >0.05). On day 14 after operation, the levels of IgA, IgG, IgM, CD3~+, CD4~+, CD4~+/CD8~+, NK in the two groups increased, the NK of the control group and the IgA, IgG, IgM, CD3~+, CD4~+, CD4~+/CD8~+ of the treatment group were significant differences compared with the 2nd day after operation(P < 0.05). Moreover, there were significant differences in IgA, IgG, CD4~+, CD4~+/CD8~+, NK between the two groups on day 14 after operation(P < 0.05). Conclusion Patients with lung cancer have immunosuppressive status in the early postoperative period. Zilongjin Tablets can improve the postoperative humoral immunity and cellular immunity of patients with lung cancer, promote the recovery of immune function and enhance their anti-tumor ability.
Objective To explore the regulatory effect of Zilongjin Tablet on immune function of postoperative patients with lung cancer from humoral immunity and cellular immunity, and to seek an effective method for comprehensive treatment of lung cancer.Methods Sixty patients with lung cancer after operation were divided into two groups according to the digital random table, 30 in the control group and 30 in the treatment group. The control group was given routine supportive treatment after operation. The treatment group was given Zilongjin Tablets(4 tablets, 3 times/d) with routine supportive treatment on day 3 after operation. The indexes of immunoglobulin(IgA, IgG, IgM), T lymphocyte subsets(CD3~+, CD4~+, CD8~+, CD4~+/CD8~+), and NK cells were compared between the two groups. Results On day 2 after operation, IgA, IgG, IgM, CD3~+, CD4~+, CD4~+/CD8~+ in the two groups decreased compared with those before operation, and the difference was statistically significant(P < 0.05), but there was no significant difference in CD8~+(P >0.05). On day 14 after operation, the levels of IgA, IgG, IgM, CD3~+, CD4~+, CD4~+/CD8~+, NK in the two groups increased, the NK of the control group and the IgA, IgG, IgM, CD3~+, CD4~+, CD4~+/CD8~+ of the treatment group were significant differences compared with the 2nd day after operation(P < 0.05). Moreover, there were significant differences in IgA, IgG, CD4~+, CD4~+/CD8~+, NK between the two groups on day 14 after operation(P < 0.05). Conclusion Patients with lung cancer have immunosuppressive status in the early postoperative period. Zilongjin Tablets can improve the postoperative humoral immunity and cellular immunity of patients with lung cancer, promote the recovery of immune function and enhance their anti-tumor ability.
引文
[1]廉政军,黄建国.晚期非小细胞肺癌预后相关因素分析[J].现代肿瘤医学, 2014, 22(1):95-97.
[2]周舟,侯炜,董军.非小细胞肺癌术后中医证型与病理类型及分期、分化之间的关系研究[J].时珍国医国药, 2018, 29(5):1126-1128.
[3]支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(1):67-78.
[4]马科,马玲,施志明.原发性支气管肺癌中医证型规范化研究[J].辽宁中医杂志, 2007, 34(4):421-422.
[5]王俞,崔书中.恶性肿瘤患者的免疫功能状态及免疫治疗研究进展[J].中国肿瘤临床,2014,41(13):876-879.
[6]喻光懋,崔健,周伟军,等.肺癌术后早期营养支持对机体免疫功能影响[J].中国肿瘤,2004,13(2):109-111.
[7]郑佳彬,李冰雪,程倩雯.非小细胞肺癌患者术后中医药治疗研究进展[J].中国肿瘤临床与康复,2017,24(1):125-128.
[8]杨忠明,曾瑞,王杰,等.加味六君子汤对肺癌术后化疗免疫功能的影响[J].成都医学院学报,2017,12(2):166-169.
[9]关念波,刘浩,林洪生.肺癌中医药治疗的研究进展及展望[J].临床肿瘤学杂志, 2013, 18(3):264-267.
[10]尚瑞国.紫龙金片联合多西他赛加顺铂方案治疗中晚期非小细胞肺癌临床疗效观察[J].中医临床研究,2016, 8(10):45-46.
[11]马惠文,方骏,王思雄.紫龙金片联合化疗对晚期肺癌的临床疗效[J].检验医学与临床,2017,14(22):3318-3320.
[12]杨爱莲,林锦培,林浩,等.紫龙金片治疗晚期恶性肿瘤临床观察[J].中草药, 2018, 49(16):3882-3884.
[13]章梁君,钟锦莎,钟辉秀,等.恶性肿瘤患者外周血淋巴细胞免疫表型检测的临床意义[J].国际检验医学杂志, 2015, 36(24):3565-3567.
[2]周舟,侯炜,董军.非小细胞肺癌术后中医证型与病理类型及分期、分化之间的关系研究[J].时珍国医国药, 2018, 29(5):1126-1128.
[3]支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(1):67-78.
[4]马科,马玲,施志明.原发性支气管肺癌中医证型规范化研究[J].辽宁中医杂志, 2007, 34(4):421-422.
[5]王俞,崔书中.恶性肿瘤患者的免疫功能状态及免疫治疗研究进展[J].中国肿瘤临床,2014,41(13):876-879.
[6]喻光懋,崔健,周伟军,等.肺癌术后早期营养支持对机体免疫功能影响[J].中国肿瘤,2004,13(2):109-111.
[7]郑佳彬,李冰雪,程倩雯.非小细胞肺癌患者术后中医药治疗研究进展[J].中国肿瘤临床与康复,2017,24(1):125-128.
[8]杨忠明,曾瑞,王杰,等.加味六君子汤对肺癌术后化疗免疫功能的影响[J].成都医学院学报,2017,12(2):166-169.
[9]关念波,刘浩,林洪生.肺癌中医药治疗的研究进展及展望[J].临床肿瘤学杂志, 2013, 18(3):264-267.
[10]尚瑞国.紫龙金片联合多西他赛加顺铂方案治疗中晚期非小细胞肺癌临床疗效观察[J].中医临床研究,2016, 8(10):45-46.
[11]马惠文,方骏,王思雄.紫龙金片联合化疗对晚期肺癌的临床疗效[J].检验医学与临床,2017,14(22):3318-3320.
[12]杨爱莲,林锦培,林浩,等.紫龙金片治疗晚期恶性肿瘤临床观察[J].中草药, 2018, 49(16):3882-3884.
[13]章梁君,钟锦莎,钟辉秀,等.恶性肿瘤患者外周血淋巴细胞免疫表型检测的临床意义[J].国际检验医学杂志, 2015, 36(24):3565-3567.